stockrow
Friday 6 November 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
917.19
22.42
+2.51%
Follow ARGX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | — | 5 | — |
| 22.63% | 0.00% | 27.07% | 0.00% | ||
| 19.54% | 0.00% | 23.15% | 0.00% | ||
ROIC |
17.19% | 0.00% | 20.71% | 0.00% | |
Return on Tangible Assets |
22.96% | 0.00% | 26.22% | 0.00% | |
Average Days of Receivables |
142.37 | 0.00 | 132.94 | 0.00 | |
Free Cash Flow per Share |
9.60 | 0.00 | 22.12 | 0.00 | |
Free Cash Flow |
588.50 | — | 1,378.46 | — | |
Capital Expenditures |
(251.29) | — | (236.98) | — | |
| Other line items | |||||
Cash ROIC |
5.44% | — | 11.49% | — | |
Accounts Receivable Turnover |
3.94 | 0.00 | 4.10 | 0.00 | |
Accounts Payable Turnover |
0.54 | 0.00 | 0.53 | 0.00 | |
Inventory Turnover |
1.15 | 0.00 | 1.50 | 0.00 | |
Average Days of Payables |
1,026.16 | 0.00 | 1,053.96 | 0.00 | |
Days of Inventory on Hand |
383.90 | 0.00 | 258.10 | 0.00 | |
Tax Rate |
0.01 | (0.01) | (0.02) | (0.01) | |
Research and Development Expense of Revenue |
32.11% | 31.47% | 31.00% | 30.29% | |
Selling, General and Administrative Expense of Revenue |
32.18% | 30.42% | 28.86% | 30.36% | |
Share Based Compensation of Revenue |
16.40% | 0.00% | 13.35% | 0.00% | |
Interest Coverage |
258.16 | 320.63 | 392.41 | 426.21 | |
Operating CF/Net income |
0.65 | 0.00 | 0.94 | 0.00 | |
Depreciation/Fixed assets |
1.40 | — | 1.45 | — | |
Capex/Depreciation |
(3.74) | — | (3.13) | — | |
Revenue per Share |
69.31 | 76.61 | 85.52 | 94.51 | |
Operating CF per Share |
13.70 | 0.00 | 25.92 | 0.00 | |
Capex per Share |
(4.10) | 0.00 | (3.80) | 0.00 | |
Capex to Sales |
0.06 | 0.00 | 0.04 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026